{
    "clinical_study": {
        "@rank": "72349", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "Healthy subjects, sequential dose escalation, IDX21459 capsules or Matching Placebo capsules, once daily, up to 7 days"
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Experimental", 
                "description": "HCV subjects genotype 1, IDX21459 capsules, once for 1 day"
            }, 
            {
                "arm_group_label": "Group C", 
                "arm_group_type": "Experimental", 
                "description": "HCV subjects genotype 1, IDX21459 capsules or Matching Placebo capsules, once daily, for 7 days"
            }
        ], 
        "brief_summary": {
            "textblock": "A multi-part study to evaluate the safety and PK of single ascending doses of IDX21549 in\n      healthy and HCV-infected subjects. The effect of food on the PK of IDX21549 will also be\n      evaluated. Antiviral activity will also be assessed in HCV-infected subjects."
        }, 
        "brief_title": "Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects", 
        "condition": "Chronic Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        All subjects\n\n          -  Subjects are in good general health.\n\n          -  Subjects have provided written informed consent form.\n\n          -  All subjects of childbearing potential must have agreed to use a double method of\n             birth control (one of which must be a barrier) from Screening through at least 90\n             days after the last dose of the study drug. HCV Subjects\n\n          -  Documented clinical history compatible with chronic hepatitis C without cirrhosis.\n\n          -  Treatment-na\u00efve\n\n          -  HCV Genotype 1\n\n        Exclusion Criteria:\n\n        All subjects\n\n          -  Pregnant or breastfeeding\n\n          -  Co-infected with hepatitis B virus (HBV) and/or human immunodeficiency virus (HIV).\n\n          -  Decompensated liver disease\n\n          -  Other clinically significant medical conditions or laboratory abnormalities."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "91", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02112942", 
            "org_study_id": "IDX-04C-001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group A", 
                    "Group B", 
                    "Group C"
                ], 
                "intervention_name": "IDX21459", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Group A", 
                    "Group C"
                ], 
                "intervention_name": "Matching Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hepatitis C virus", 
            "HCV"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Montreal", 
                    "country": "Canada", 
                    "state": "Quebec"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase I Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects", 
        "other_outcome": {
            "description": "Change in plasma HCV RNA and emergence of resistance mutations", 
            "measure": "Antiviral activity", 
            "safety_issue": "No", 
            "time_frame": "Up to 35 days"
        }, 
        "overall_contact": {
            "email": "clinicaltrials@idenix.com", 
            "last_name": "John Z Sullivan-Bolyai, MD", 
            "phone": "877-433-6491"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Proportion of subjects experiencing adverse events.", 
            "measure": "Safety and tolerability assessment", 
            "safety_issue": "Yes", 
            "time_frame": "up to 35 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02112942"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Plasma and urine concentrations of IDX21459 and its metabolite/s.", 
            "measure": "Pharmacokinetic", 
            "safety_issue": "No", 
            "time_frame": "Up to 120 hours post dose"
        }, 
        "source": "Idenix Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Idenix Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}